Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Sativex in Severe Renal Impairment
NCT02325024Phase 1Withdrawn
- Sponsor
- GW Pharmaceuticals
- Start
- Jan 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of cannabidiol in multiple sclerosis (MS) and Spasticity (2 arms), sponsored by GW Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration of THC at 48 hours, Area Under the Curve for THC at 48 hours and 4 more. Planned start Jan 2016; status: withdrawn.
02
Drugs
cannabidiol
03
Conditions
multiple sclerosis (MS)Spasticity
Beyond the preview
Go deeper on NCT02325024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02325024.